These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 4622605)

  • 1. [Pseudomonas aeruginosa infections].
    Tanaka E
    Naika; 1972; 29(2):286-90. PubMed ID: 4622605
    [No Abstract]   [Full Text] [Related]  

  • 2. [Sensitivity in vitro to antibiotics and chemotherapeutic agents in various hospital strains of Pseudomonas aeruginosa].
    Bertaggia A; De Negri M
    Boll Ist Sieroter Milan; 1974; 50(1):45-53. PubMed ID: 4204863
    [No Abstract]   [Full Text] [Related]  

  • 3. [Does a rational therapeutic plan exist for nosocomial bacteremia caused by Pseudomonas aeruginosa?].
    Torné J; García Flores A; Tomás S; Serrano R
    Med Clin (Barc); 1987 Oct; 89(13):572. PubMed ID: 3121961
    [No Abstract]   [Full Text] [Related]  

  • 4. [In vitro/in vivo discrepancy of antibiotic activity against Pseudomonas aeruginosa].
    Gerber AU
    Fortschr Med; 1985 Sep; 103(34):807-10. PubMed ID: 3935553
    [No Abstract]   [Full Text] [Related]  

  • 5. [Metallo-beta-lactamases producing Pseudomonas aeruginosa in Algeria].
    Aggoune-Khinache N; Bensersa D; Henniche FZ; Daoudi M; Abdouni MA; Chabani A; Tiouit D; Naim M
    Med Mal Infect; 2009 Jun; 39(6):413-4. PubMed ID: 19111417
    [No Abstract]   [Full Text] [Related]  

  • 6. [Trend of therapy in Pseudomonas aeruginosa infections].
    Jannuzzi C; Tassara A
    G Mal Infett Parassit; 1971 Nov; 23(11):1051-4. PubMed ID: 5004852
    [No Abstract]   [Full Text] [Related]  

  • 7. [Role of antibiotics in infections due to Pseudomonas aeruginosa].
    Výmola F; Jedlicková Z
    Cesk Epidemiol Mikrobiol Imunol; 1972 Jul; 21(4):176-81. PubMed ID: 4262242
    [No Abstract]   [Full Text] [Related]  

  • 8. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
    Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
    Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
    [No Abstract]   [Full Text] [Related]  

  • 9. Colistin: an antimicrobial for the 21st century?
    Stein A; Raoult D
    Clin Infect Dis; 2002 Oct; 35(7):901-2. PubMed ID: 12228836
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa.
    Scheetz MH; Esterly JS; Malczynski M; Postelnick M; Qi C
    Diagn Microbiol Infect Dis; 2009 Aug; 64(4):465-7. PubMed ID: 19394788
    [No Abstract]   [Full Text] [Related]  

  • 11. [A comparative study of cephotaxime and other antimicrobial agents in relationship to Pseudomonas aeruginosa (author's transl)].
    García Martos P; Rodríguez Sarmiento MT; García Herruzo J; Fernández Gutiérrez del Alamo C; Romera Cano MA; Martínez País Romaní R
    Med Clin (Barc); 1982 Feb; 78(4):148-51. PubMed ID: 6279982
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antibiotic resistance of some Pseudomonas aeruginosa isolates].
    Matinca D; Vancea D; Boboş C; Serban O
    Bacteriol Virusol Parazitol Epidemiol; 2003; 48(2-3):157-61. PubMed ID: 15341333
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antibiotic, triphenylmethane dyes and boric acid in increased occurrence of Pseudomonas aeruginosa].
    Möhlenbeck F
    Z Haut Geschlechtskr; 1970 Apr; 45(8):329-32. PubMed ID: 4327229
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effective agents against Pseudomonas pyocyanea (proceedings)].
    Meyer-Rohn J
    Z Hautkr; 1976; 51 Suppl 2():106-8. PubMed ID: 827860
    [No Abstract]   [Full Text] [Related]  

  • 15. Should we be afraid of the Green Monster?
    Rumbaugh K
    Crit Care Med; 2009 May; 37(5):1826-7. PubMed ID: 19373066
    [No Abstract]   [Full Text] [Related]  

  • 16. Current therapies for pseudomonas aeruginosa.
    Giamarellou H; Kanellakopoulou K
    Crit Care Clin; 2008 Apr; 24(2):261-78, viii. PubMed ID: 18361945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002.
    Mohr JF; Jones A; Ostrosky-Zeichner L; Wanger A; Tillotson G
    Int J Antimicrob Agents; 2004 Oct; 24(4):346-51. PubMed ID: 15380259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of Pseudomonas aeruginosa infections].
    Klastersky J
    Acta Clin Belg Suppl; 1971; 7():75-8. PubMed ID: 5004796
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of multidrug-resistant Pseudomonas aeruginosa infections: more attention required to in-vitro studies.
    Zavascki AP
    Clin Microbiol Infect; 2005 Oct; 11(10):856-7. PubMed ID: 16153266
    [No Abstract]   [Full Text] [Related]  

  • 20. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
    Hocquet D; Muller A; Blanc K; Plésiat P; Talon D; Monnet DL; Bertrand X
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1173-5. PubMed ID: 18180356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.